Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs

Joshua J. Gagne (), Jennifer R. Popovic, Michael Nguyen, Sukhminder K. Sandhu, Patty Greene, Rima Izem, Wenlei Jiang, Zhong Wang, Yueqin Zhao, Andrew B. Petrone, Anita K. Wagner and Sarah K. Dutcher
Additional contact information
Joshua J. Gagne: Brigham and Women’s Hospital, Harvard Medical School
Jennifer R. Popovic: Harvard Medical School, Harvard Pilgrim Health Care Institute
Michael Nguyen: Center for Drug Evaluation and Research, US Food and Drug Administration
Sukhminder K. Sandhu: Center for Drug Evaluation and Research, US Food and Drug Administration
Patty Greene: Center for Drug Evaluation and Research, US Food and Drug Administration
Rima Izem: Center for Drug Evaluation and Research, US Food and Drug Administration
Wenlei Jiang: Center for Drug Evaluation and Research, US Food and Drug Administration
Zhong Wang: Center for Drug Evaluation and Research, US Food and Drug Administration
Yueqin Zhao: Center for Drug Evaluation and Research, US Food and Drug Administration
Andrew B. Petrone: Harvard Medical School, Harvard Pilgrim Health Care Institute
Anita K. Wagner: Harvard Medical School, Harvard Pilgrim Health Care Institute
Sarah K. Dutcher: Center for Drug Evaluation and Research, US Food and Drug Administration

Drug Safety, 2018, vol. 41, issue 12, No 6, 1313-1323

Abstract: Abstract Introduction Nearly 90% of drugs dispensed in the US are generic products. Objective The aim of this study was to develop and implement a tool for analyzing manufacturer-level drug utilization and switching patterns within the US Food and Drug Administration’s Sentinel system. Methods A descriptive tool was designed to analyze data in the Sentinel common data model and was tested with two case studies—metoprolol extended release (ER) and lamotrigine ER—using claims data from four Sentinel data partners. We plotted initiators of each brand and generic product over time. For metoprolol ER, we evaluated rates of switching from generics around the time of manufacturing issues. For lamotrigine ER, we examined rates of switching back to the brand among those who switched from brand to generic. Results We identified 1,651,285 initiators of metoprolol ER products between July 2008 and September 2015. We observed a large decrease in monthly metoprolol ER initiators (from 25,465 in December 2008 to 13,128 in February 2009), corresponding to recalls by generic manufacturers. We observed simultaneous increases in utilization of the authorized generic and brand products. We identified 4266 initiators of lamotrigine ER with an epilepsy diagnosis between January 2012 and September 2015. Among those who switched from brand to generic, the cumulative incidence of switching back was close to 20% at 2 years. Switchback rates were higher for the first available generic products. Conclusions This developed tool was able to elucidate novel utilization and switching patterns in two case studies. Such information can be used to support surveillance of generic drugs and biosimilars.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0709-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0709-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0709-4

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().